Collectively, our data suggested that miR-550a-3-5p treatment sensitized BRAF inhibitor resistance through YAP inhibition with reduced AKT activity in BRAF-mutant colon cancer and melanoma cells, which provided evidence for the potential therapeutic role of miR-550a-3-5p in BRAF inhibitor-resistant colon cancers and melanomas. Here, YAP1 is linked to colonic neoplasm.